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Abstract
Background: DNA originating from degenerate tumour cells can be detected in the circulation in many tumour
types, where it can be used as a marker of disease burden as well as to monitor treatment response. Although
circulating tumour DNA (ctDNA) measurement has prognostic/predictive value in metastatic prostate cancer, its
utility in localised disease is unknown.
Methods: We performed whole-genome sequencing of tumour-normal pairs in eight patients with clinically localised
disease undergoing prostatectomy, identifying high confidence genomic aberrations. A bespoke DNA capture and
amplification panel against the highest prevalence, highest confidence aberrations for each individual was designed
and used to interrogate ctDNA isolated from plasma prospectively obtained pre- and post- (24 h and 6 weeks) surgery.
In a separate cohort (n = 189), we identified the presence of ctDNA TP53 mutations in preoperative plasma in a
retrospective cohort and determined its association with biochemical- and metastasis-free survival.
Results: Tumour variants in ctDNA were positively identified pre-treatment in two of eight patients, which in both
cases remained detectable postoperatively. Patients with tumour variants in ctDNA had extremely rapid disease
recurrence and progression compared to those where variants could not be detected. In terms of aberrations targeted,
single nucleotide and structural variants outperformed indels and copy number aberrations. Detection of ctDNA TP53
mutations was associated with a significantly shorter metastasis-free survival (6.2 vs. 9.5 years (HR 2.4; 95% CIs 1.2–4.8,
p = 0.014).
Conclusions: CtDNA is uncommonly detected in localised prostate cancer, but its presence portends more rapidly
progressive disease.
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Background
The majority of men diagnosed with localised prostate
cancer are effectively cured with surgery and/or radi-
ation therapy [1]; however, a proportion of patients will
experience disease recurrence, often associated with high
grade and/or locally advanced tumours [2]. Predicting
patients at highest risk of relapse remains challenging, as
while clinical prognostic factors are certainly helpful [3],
they do not always provide the full picture for an indi-
vidual patient. The ability to accurately identify these pa-
tients may have clinical implications, as they have the
potential to benefit from systemic treatment intensifica-
tion strategies. While the value of these systemic treat-
ments in metastatic hormone-sensitive prostate cancer
(mHSPC) is undisputed (ENZAMET [4], ARCHES [5],
TITAN [6], STAMPEDE [7, 8], LATITUDE [9], CHAA
RTED [10]), utility in early-stage disease is less clear.
However, this is an area of intense investigation in which
treatment strategies will continue to evolve [11, 12].
Prognostic biomarkers to predict risk of metastatic dis-
ease development are thus urgently required, not only to
facilitate discussions with patients/caregivers around ex-
pected outcomes, but also to inform clinical trial design
and perhaps ultimately guide optimal management.
A number of molecular biomarkers for use on pri-
mary prostate cancer tissue are already in clinical use
(for example Decipher [13], Oncotype [14], and Prolaris
[15]) and can be used to predict the presence of adverse
pathology or recurrent disease post primary treatment.
These transcription-based assays require the use of
tumour tissue from the diagnostic biopsy specimen,
which in the context of the well-described molecular
heterogeneity of primary prostate cancer [16] as well as
the sampling error inherent with traditional biopsy
strategies [17], has led to the exploration of circulating
biomarkers as a ‘whole tumour’ sampling technique. An
array of different biomarkers have been investigated, in-
cluding circulating tumour cells (CTCs), exosomes and
circulating tumour DNA (ctDNA), although most of
these have been in the metastatic castration-resistant
setting (mCRPC), where tumour burden is higher [18,
19]. Use of these biomarkers in the localised setting,
where disease volume is considerably lower, may pose
significant challenges. In this context, the use of ctDNA
has some appeal, due to the ability to amplify the signal
against background noise, as well as the increasing an-
notation of particular genomic features as important
drivers of clinical outcome [20]. However, the current
analytical sensitivity and limit of detection of most ‘off
the shelf’ ctDNA assays is inadequate to reliably call
low-frequency variants observed in early prostate can-
cer [21]. One of the ways to overcome this is to use
ultradeep sequencing using targeted panels looking for
patient-specific alleles.
This personalised assay approach has recently been in-
vestigated in localised prostate cancer [22]. As part of a
broader attempt to identify ctDNA in a large cohort of
patients with localised disease, Hennigan and colleagues
performed multiregional sequencing to identify patient-
specific variants present clonally or at high allele fre-
quency within the primaries of nine patients, followed
by targeted deep sequencing of these variant sites within
plasma-derived cell-free DNA. Despite readily detecting
ctDNA in patients with metastatic disease, they were un-
able to positively identify ctDNA in any patient by this
or any other approach. Although the authors provide a
number of plausible biological reasons for this negative
finding, including low rates of cell proliferation and
ctDNA shedding in localised disease, as well as more re-
stricted access to the vasculature compared to metastatic
lesions, a further possibility is that the number of pa-
tients with truly high-risk disease within their cohort
was too low to detect a positive signal. Certainly ctDNA
measurement has proven feasible and clinically meaning-
ful in detecting the presence of ‘micrometastatic disease’,
and be prognostic for recurrence, in other tumour types
in the localised setting [23, 24].
In this study, we performed panel-based targeted se-
quencing informed by individual patient tumour WGS,
as well as tagged-amplicon deep sequencing (TAm-Seq)
across the TP53 gene in two separate cohorts of patients
with localised prostate cancer, with an emphasis on
high-risk disease [25]. We found that ctDNA was detect-
able in both the pre- and post-operative setting, and that
pre-operative detection was associated with a significant
reduction in metastasis-free survival.
Methods
Study cohorts
Two separate patient cohorts were used for this study.
For tumour-based WGS analysis (WGS cohort), we pro-
spectively enrolled 10 consecutive patients presenting to
a single surgeon with clinically localised prostate cancer
suitable for prostatectomy with curative intent. For the
TAm-Seq analysis (TAm-Seq cohort, n = 189), patients
were selected from a prospectively collected and clinic-
ally annotated institutional bio-repository [26]. Patients
were prioritised based on the length of follow-up,
enriched for high-risk disease and recurrence events.
Collection and use of material had Institutional Review
Board approval (HREC# 626-14).
Whole-genome sequencing and analysis
A summary of the blood and prostatectomy specimens
available for WGS is shown in Additional file 1: Table
S1. Patients with both tumour and matched germline
DNA samples from a peripheral blood buffy coat speci-
men were suitable for WGS to discover patient-specific
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variants. Genomic DNA extracted from blood and tissue
samples were prepared using the TruSeq® DNA PCR-
free sample preparation kit (Illumina, San Diego, CA,
USA). The libraries were sequenced as paired-ends (2 ×
150 cycles) using a HiSeqX platform to an average depth
of >30x for germline and >100x for tumour samples, fol-
lowing alignment to the Human Reference sequence
(hg19) using iSAAC-03.16.02.19 and removal of dupli-
cate read-pairs. Variant calling was performed using the
Illumina IsaacVariantCaller (2.6.53.23) [27].
Enrichment panel design and targeted sequencing and
analysis
A subset of somatic variants identified through whole-
genome sequencing were included on the panel for each
patient. Variants were preferentially selected for inclu-
sion where they occurred in genes previously implicated
in cancer [28] or prostate cancer specifically [21]. A
range of SNVs, indels and structural variants (SVs) were
targeted. The final design targeted 88 kb of the genome.
Target regions were uploaded to Illumina DesignStudio
(www.designstudio.illumina.com) for probe design. A
single probe was selected for small variants, while SVs
were targeted using a probe from each side of the re-
arrangement junction. For indels, a probe adjacent to
the variant was selected (Additional file 2: Figure S1).
Probes were validated on fresh frozen tumour DNA to
confirm successful design and synthesis, and a list of
genomic variants targeted in each patient is provided in
Additional file 3: Table S2.
For each patient, blood was collected from up to three
timepoints in EDTA tubes for ctDNA analysis; sample
(a) was taken pre-surgery, sample (b) 24 h post-surgery
and sample (c) 6 weeks post-surgery. Immediately after
collection, plasma was collected following a double spin
(820g for 10 min; 16,000g for 10 min) and stored at −
80 °C until analysis. Circulating DNA was extracted
using the QIAamp Circulating Nucleic Acid Kit (Qiagen,
Hilden, Germany), and DNA quality was assessed using
an Agilent BioAnalyzer and quantified using the Qubit
method (Thermofisher, Delaware, USA).
Input into library preparations was between 28 and
60 ng of ctDNA, with a median value of 39 ng as de-
termined by Qubit. Enriched libraries were prepared
from ctDNA extracted from plasma using the Tru-
Sight® Tumor 170 library prep kit supplemented with
the TruSight® Oncology UMI Reagents (Illumina Inc.).
Adapters containing UMIs enable detection of genu-
ine, very low-frequency variants through the reduction
of background noise in sequencing data. Due to the
small fragment length of the starting material, the
DNA shearing step of the TST170 protocol was omit-
ted. Libraries were enriched with the custom panel
then sequenced as paired-ends (2 × 150 bp) plus
indexing reads on NextSeq High output. Five or six
samples were loaded per flow cell to achieve ~ 40,
000x raw depth per sample.
Samples were processed using an Illumina R&D ana-
lysis pipeline to take advantage of the UMIs incorpo-
rated during library preparation. Reads were grouped
into read families by alignment to the hg19 human refer-
ence sequence followed by collapsing and stitching into
unique fragments utilising start and stop positions, UMI
barcodes and the paired read (where present) to generate
collapsed BAM files. These collapsed families of reads
are low noise and high confidence. Positions targeted by
the panel were reviewed using Integrative Genomics
Viewer (IGV; The Broad Institute) to confirm the pres-
ence or absence of the targeted variants.
TP53 TAm-Seq
DNA was isolated from archived plasma samples
stored in liquid nitrogen using the QIAamp Circulat-
ing Nucleic Acid Kit and quantified using Qubit Mo-
lecular Probes dsDNA high sensitivity assay kit
(Invitrogen, CA, USA). For amplicon production, for-
ward and reverse primers (Additional file 2: Figure
S2) tiling across the TP53 gene were combined for
use in eight separate PCR reactions per patient. Input
was 2 ng of DNA, which was added to a PCR reaction
mix composed of 2 μl of primer (0.5 μl ea. @ 10 μM)
and 10 μl Q5 DNA pol 2X master mix made up to
20 μl with MQ water. The reaction was run on a ViiA
7 PCR machine with the following settings: initial de-
naturation at 95 °C × 1 min, then cycle denaturation
at 95 °C × 10s following by annealing at 58 °C × 1 s
and then extension at 72 °C × 18 s for 38 cycles.
Amplicons were then combined into two pools of
non-overlapping products and cleaned with the Qia-
gen QIAquick PCR purification kit following the
manufacturer’s instructions. DNA was quantified
using a nanodrop and 100 ng of DNA of each pool
end repaired and adaptor ligated using NEBNext
Adaptors for Illumina according to the manufacturer’s
instructions. Following a AMPure XP bead clean-up,
a second round of PCR amplification was performed
in a total reaction volume of 50 μl consisting of 20 μl
of adaptor ligated DNA fragments, 25 μl Q5 2X mas-
ter mix, 2.5 μl index primer (10 μM) and 2.5 μl uni-
versal PCR primer (10 μM). PCR amplification was
then performed in a thermocycler under the following
conditions: initial denaturation at 98 °C × 30 s, then
cycle denaturation at 98 °C × 10 s following by an-
nealing/extension at 65 °C × 75 s for 8 cycles, with a
final extension at 65 °C for 5 min. The reaction mix-
ture was then cleaned again using AMPure XP beads
following the manufacturer’s instructions at a ratio of
0.9:1 beads to ligation mixture. The pool was then
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quantified and quality checked on a Bioanalyzer (Agi-
lent, CA, USA) before sequencing on a MiSeq (Illu-
mina Inc.). A detailed description of the experimental
procedure is provided as supplementary information
(Additional file 4; Supplementary Methods).
TAm-Seq analysis
For each sample in the study, paired-end DNA sequen-
cing reads (length 151 bp) were aligned to the human
genome reference hg19 using BWA mem (version
0.7.17). Reads were assigned to their corresponding PCR
amplicons based on their alignment coordinates. To be
considered for further analysis, reads were required to
have a minimum alignment length of 75 bp, a minimum
overlap of at least 75% of their target amplicon and no
more than 2 bp edit distance from the reference genome.
Using the filtered set of reads, the frequency of each
DNA base was counted at each genomic locus within
the target PCR amplicon regions for each sample. Using
the control samples, at each locus, a null model was
computed to represent the expected distribution of allele
counts when no variant is present. Allele count data was
modelled (with add-one smoothing) using the Dirichlet
Multinomial distribution with best hyperparameter com-
puted by maximising the log-likelihood function using
the Newton-Raphson method. For each locus in the case
samples, the allele count was compared with the null
model. The weight of evidence against the null was mea-
sured by the Bayes factor B. The prior distribution of the
count data of the case samples was given by a Dirichlet
distribution on a 3-simplex, with all pseudocounts set to
½ (as per Jeffrey’s Prior on a multinomial distribution).
Variant allele frequencies (VAF) were computed using
the maximum a posteriori (MAP) estimate on the
posterior distribution marginalised to the component
representing the non-reference allele. After filtering
out any variants with gnomAD (gnomad.broadinsti-
tute.org) population frequency greater than 1%, a set
of high-confidence variants was selected based on
having a minimum filtered depth of coverage of 500
reads, a minimum log Bayes factor of 6 (equivalent to
posterior odds against the null hypothesis of 50:1)
and a cohort frequency of less than four samples.
The predicted pathogenicity of detected variants was
assessed using Varsome [29].
Clinical outcomes
Postoperative PSA data was collected prospectively in all
TAm-Seq patients. Biochemical recurrence was defined
as a single post-operative PSA reading of > 0.2 ng/ml, or
a rising measurement below this that was determined to
represent a recurrence by the treating physician and led
to the institution of salvage therapy. The presence of
metastasis and mode of diagnosis was determined by
retrospective chart review. For patients without recur-
rence or metastasis, follow-up was censored at the time
of their last PSA or clinical review as appropriate. To
compare biochemical recurrence-free and metastasis-
free survival between groups, Kaplan-Meier curves were
generated and compared using a two-sided logrank test,
with significance assumed at p < 0.05.
Results
Paired tumour and germline WGS was completed on
eight patients, the clinical and pathological characteris-
tics of whom are shown in Table 1. Consistent with con-
temporary practice, all patients had intermediate- or
high-risk disease at the time of radical treatment, and
two patients underwent salvage prostatectomy for radio-
recurrent disease. Patients at risk of metastasis based on
their disease characteristics were staged pre-operatively
with a technetium-99 m-MDP whole body bone scan
and cross-sectional imaging (MRI pelvis + lumbar spine
or CT abdomen/pelvis) as appropriate. No patient had
evidence of metastatic disease at the time of surgery.
The number of genomic aberrations identified by
tumour WGS per patient is summarised in Additional
file 1: Table S3. The average mutation rate was 5.51
SNVs per megabase, consistent with a high-risk disease
cohort [21]. The category of features selected for
targeted capture and sequencing and a breakdown of
variants targeted versus those detected in ctDNA are
summarised in Fig. 1. Genomic features of prostate can-
cer were identified in ctDNA in two of eight patients in-
vestigated with only SNVs and SVs being detected.
Interestingly, while all SNVs and SVs targeted in patient
11196_3 were detectable in the ctDNA, we could find no
evidence of the targeted small indels, despite their pres-
ence at high frequency in the tumour WGS data and
good coverage in these regions. Similarly CNAs detected
in ctDNA in general correlated poorly with tumour
WGS and could not be reliably called at the ctDNA
levels observed in this localised cohort.
Changes in specific variants identified in the ctDNA in
patients 11196_3 and 11201_4 over time are shown in
Figs. 2 and 3, along with a summary of the clinical
course of their disease post-surgery. Two timepoints
(pre-operative and 24 h post-surgery) were available for
patient 11196_3, who showed some evidence of a treat-
ment effect, with a decrease in the variant allele fre-
quency observed for almost all of the ctDNA variants
measured (Fig. 2a). A similar effect was not consistently
observed in patient 11201_4, with an inexorable increase
in variant allele frequency of measured variants observed
across the three timepoints. Although all patients were
negative for metastatic disease using conventional im-
aging at the time of surgery, patients in whom ctDNA
was detectable pre-treatment had strikingly aggressive
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post-treatment clinical courses compared to patients
with no detectable ctDNA (Additional file 2: Figure S3),
characterised by early disease recurrence and metastases,
relatively poor response to systemic treatments, and pro-
gression to death within 2.5 years.
To extend these findings, we performed targeted se-
quencing of plasma DNA collected from patients under-
going prostatectomy for presumed localised prostate
cancer (n = 189), focussing on TP53, one of the most
commonly mutated genes in prostate cancer, and one
that is positively enriched for in metastatic disease (in-
cluding in patient 11196_3) [20, 30]. As indicated in the
study description above, the cohort was selected to en-
rich for patients with high-risk and recurrent disease, to
maximise the chances of detecting ctDNA in some pa-
tients, the clinical and pathological characteristics of
whom are summarised in Table 2. After filtering, the
mean depth of coverage within the target regions was
3198 reads. Positive detection of TP53 ctDNA variants
was identified in 22 cases (12%), with no variants de-
tected in the remainder (Additional file 1: Table S4).
The median and mean coverage depth for called variants
was 9892x and 12,695x respectively. Fourteen out of 21
variants identified were predicted to be pathogenic or
Table 1 Clinical and pathological characteristics of the WGS study cohort
Sample Age PSA Prior RT cT Bx GG Staging RP GG pT Vol (cc)
11193_2 70 26.9 y cT1c 5 MRI
WBBS
5 pT3b 21.3
11196_3 57 9.3 y cT1c 3 MRI
WBBS
3 pT3b 2.1
11201_4 64 8.1 n cT3a 5 CT
WBBS
5 pT3b 18.5
11199_5 67 7.8 n cT2a 2 MRI 3 pT3a 15.2
11219_6 58 6.5 n cT1c 2 MRI 2 pT3a 2.1
11231_9 59 6.1 n cT1c 2 MRI 2 pT2c 3.7
11242_10 61 4.1 n cT2a 2 CT
WBBS
2 pT3a 3.7
11243_11 76 7.9 n cT2a 5 CT
WBBS
3 pT3a 7.5
PSA prostate-specific antigen, RT radiotherapy, cT clinical stage, Bx diagnostic biopsy, GG International Society of Urological Pathology Grade Group, RP radical
prostatectomy, pT pathological stage, Vol (cc) tumour volume (cm3)
Fig. 1 a Targeted genomic variants in each patient by category. Per patient summary of b SNVs, c SVs and d small indels targeted and detected
in any ctDNA sample by deep targeted sequencing
Lau et al. Genome Medicine           (2020) 12:72 Page 5 of 11
likely pathogenic, with only one variant classed as likely
benign. There was no significant difference in biochem-
ical recurrence-free survival (BFS) between patients with
or without a detectable variant (Fig. 4a), with a mean
BFS of 2.4 vs. 3.7 years (HR 1.4; 95% CIs 0.76–2.6, p =
0.28). In contrast, metastasis-free survival (MFS) was sig-
nificantly shorter in patients positive for a variant
(Fig. 4b), with mean MFS of 6.2 vs. 9.5 years (HR 2.4;
95% CIs 1.2–4.8, p = 0.014). Similar results were
observed using a contingency analysis (Additional file 1:
Table S5).
Discussion
Although ctDNA is reported to be relatively abundant in
metastatic prostate cancer, at the time of initiation of
this study, it was unclear if ctDNA could be detected in
patients with localised disease, as well as the clinical im-
plications of its presence. A number of early studies
Fig. 2 a Selected variant frequency observed in tumour whole-genome sequencing (WGS) and circulating tumour DNA (ctDNA) at indicated
timepoints in patient 3. b Summary of clinical history of patient 3 post-surgery with ctDNA sampling indicated by red arrows
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identified an association between total cell-free plasma
DNA concentration and the presence of cancer and bio-
chemical recurrence post prostatectomy [31–33]; how-
ever, the first study to investigate circulating tumour
DNA in this setting has only recently been reported
[22]. In this study, Hennigan and colleagues used ultra-
low pass whole-genome sequencing of cell-free plasma
DNA in over 100 patients with clinically localised dis-
ease prior to prostatectomy, as well as deep targeted se-
quencing of a bespoke panel of single nucleotide
variants/indels selected as clonal or major subclonal
events, based on individual multiregional whole exome
sequencing in a subset of nine patients. Despite the tech-
nical robustness of the methodology evidenced by con-
sistent identification of ctDNA in patients with
established metastatic disease using these approaches,
they were unable to identify any ctDNA in any patient
with clinically localised disease.
Here we have been able to identify ctDNA in two of
eight patients with localised disease using a personalised
approach based on individual whole-genome sequencing
followed by deep-targeted sequencing of selected vari-
ants in plasma cell-free DNA. Furthermore, in a retro-
spective analysis of patient samples (enriched for high-
risk patients) using the previously described TAm-Seq
method to tile across a single gene, we have been able to
detect ctDNA in 22 out of a further 189 patients. Im-
portantly, we were able to demonstrate that detection of
ctDNA in the pre-prostatectomy setting has prognostic
implications and is associated with more rapid progres-
sion to metastatic disease in both analyses. This is of
clear clinical relevance, given that MFS is a strong surro-
gate of overall survival in localised prostate cancer [34].
Despite differences in sequencing and analysis
methods between the studies, at least for the individual
targeted analysis, it is likely that clinical differences
Fig. 3 a Selected variant frequency observed in tumour whole-genome sequencing (WGS) and circulating tumour DNA (ctDNA) at indicated
timepoints in patient 4. b Summary of clinical history of patient 4 post-surgery with ctDNA sampling indicated by red arrows
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between the cohorts are the basis of the observed dis-
crepancy. For instance in the Hennigan study, although
8/9 patients who underwent tissue and plasma cell-free
DNA sequencing had locally advanced and/or high grade
tumours, only one patient experienced a biochemical re-
currence with 24months of surgery, and no patients
were reported to progress to metastasis. In contrast,
from our cohort, three patients had primary PSA
persistence, and a further two patients experienced bio-
chemical recurrence within 24 months. Of these, ctDNA
was only detectable in 2 patients, both of whom had pri-
mary PSA persistence and very rapid disease trajectories,
characterised by early progression to overt metastatic
disease and death. Patient 11196_3 had a moderately
sized tumour, with only ISUP grade group 3 disease at
prostatectomy, but was radiorecurrent, with extensive
extracapsular extension and invasion into the seminal
vesicle. Prominent lymphovascular invasion, a patho-
logical feature associated with aggressive disease [35],
was also observed in large extraprostatic vessels. The
second patient 11201_4 had more conventional high-risk
disease, with a large volume, locally advanced ISUP
grade group 5 tumour. In both cases, pre-treatment sta-
ging with conventional imaging was negative for meta-
static disease, although the likelihood of tumour cell
dissemination at the time of diagnosis was high. Simi-
larly, the cohort we used for the TAm-Seq analysis is a
higher risk cohort than that used for ultra-low pass
whole-genome analysis, based on a higher median PSA
and the proportion of patients with ISUP grade group 4/
5 disease, which is not unexpected given this study
group was enriched for recurrent and metastatic events
post-prostatectomy. However, there may be some add-
itional technical issues, as despite including probes for
copy number variants in the targeted panel for 7/8 pa-
tients (including patients 11196_3 and 11201_4), we
were unable to positively identify any ctDNA CNAs con-
cordant with tumour whole-genome sequencing data
using this particular custom panel. It may be that even
in patients with detectable ctDNA in the clinically local-
ised setting, absolute levels are too low to make
confident calls with the sensitivity of the assay used in
this study, at least not without a considerable investment
is assay development and control samples for normalisa-
tion. Certainly, it has been suggested that tumour DNA
fractions > 35% are required to accurately detect CNA
events [36], particularly deletions, and this far exceeds
the levels observed in our study, even with extremely ag-
gressive localised disease.
A key finding in this study is the consistent association
between pre-treatment ctDNA detection and clinical
outcomes, which may serve as a useful adjunct to select
patients for treatment intensification at the time of diag-
nosis. Creating a custom panel based on sequencing of
the primary tumour and identifying individual-specific
variants may be the most sensitive way of positively
identifying ctDNA in patients, but outside of particularly
invested centres, its use as a clinical strategy is limited
by the cost and turn-around time. An alternative ap-
proach is to target common variants identified in a
landscape-type analysis [21]. We were able to measure
SVs and SNVs consistently, suggesting that a strategy
Table 2 Clinical and pathological characteristics of the TAm-Seq
study cohort
n 189
Age (years)
Median 63
IQR 58–67.6
PSA ng/ml
Median 7.5
IQR 5.3–12.95
cT
1 105 (55.6%)
2 63 (33.3%)
3 21 (11.1%)
Biopsy ISUP Grade Group
1 33 (17.5%)
2 61 (32.3%)
3 29 (15.3%)
4 35 (18.5%)
5 31 (16.4%)
pT
2 88 (46.6%)
3a 60 (31.7%)
3b 41 (21.7%)
Prostatectomy ISUP Grade Group
1 10 (5.3%)
2 63 (33.3%)
3 61 (32.3%)
4 11 (5.8%)
5 44 (23.3%)
Tumour volume (cc)
Median 3.35
IQR 1.5–7.37
Biochemical recurrence
No 90 (47.6%)
Yes 99 (52.4%)
Metastases
No 117 (61.9%)
Yes 49 (35.9%)
Not reported 23 (12.2%)
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built around detecting this class of variants based on ob-
served frequency in landscape analysis may be the best
approach. One concern however is that SNVs in prostate
cancer are rarely located in ‘hot-spot’ regions, and break-
point sites vary significantly between patients, requiring
coverage of a relatively large genomic region to increase
sensitivity. Certainly using this approach tiling across
TP53, mutations of which are enriched in patients with
metastatic disease, we were able to identify ctDNA in
just under 12% of patients, where it again was associated
with the development of metastatic disease. Clearly, all
patients with potentially detectable ctDNA levels were
not identified, as many patients who were TP53 ctDNA
negative also experienced metastatic progression post-
operatively. Extending the number of variants assessed
will likely increase test sensitivity [37], but for an ‘off-
Fig. 4 Kaplan-Meier curves demonstrating a biochemical recurrence and b metastasis-free survival in a cohort of 189 patients undergoing
prostatectomy categorised by pre-treatment TP53 ctDNA status
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the-shelf’ assay, an optimal ‘sweet spot’ that balances test
complexity, cost and diagnostic performance will need
to be determined.
There are a number of limitations to our study that
warrant some consideration. Undiagnosed clonal haem-
atopoiesis of indeterminate potential (CHIP), of which
TP53 mutation is a relatively frequent driver, has been
shown to be a common source of variants detected in
deep cell-free DNA analyses and ideally should be con-
trolled for by concomitant sequencing of white blood
cell DNA which we have not performed [38, 39]. How-
ever, we observe that two of the variants (chr17:
7578475_G>A and chr17:7577121_G>A) identified by
TAm-Seq were also detected in previous whole-genome
sequencing on the same tumour samples [30]. Enrich-
ment for a known driver of prostate cancer spread in the
cohort of patients who progress to clinical metastases
suggests that the majority of identified variants are
tumour related, but further work is required to confirm
this. In addition, the TAm-seq assay had reasonably low
sensitivity, which was not unexpected given the reason-
ably low frequency of TP53 mutations in localised pros-
tate cancer [20, 21]. However despite these issues with
sensitivity and specificity, the TAm-Seq analysis sup-
ported the association between ctDNA detection and ag-
gressive disease in the localised setting. It is also
important to note that all patients in our study were
staged using conventional imaging. Given the reported
greater sensitivity of molecular staging, for example,
PSMA-PET in detecting low volume disease in the re-
currence setting [40], such imaging modalities may bet-
ter detect patients with micrometastatic disease pre-
treatment. Whether such imaging gives potentially the
same information or is complementary with ctDNA de-
tection will need to be determined.
Conclusions
In summary, using two separate cohorts and two differ-
ent approaches, we have found that ctDNA can be iden-
tified in patients with clinically localised prostate cancer
and is associated with a significantly shorter time to
metastatic progression. Efforts to improve levels of de-
tection, specificity and universal applicability of ctDNA
detection in this setting are warranted.
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